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 College oAbstract Introduction: Acute liver failure (ALF), like sepsis, is associated with an overwhelming
activation of the immune response in which hepatic and circulating inﬂammatory cytokines play a
pivotal role. Cholinesterase inhibition has been shown to have anti-inﬂammatory properties in
experimental sepsis. We investigated the role of neostigmine in attenuating D-galactosamine (D-
GalN)-induced ALF.
Methods: Thirty-six female wistar rats were randomly allocated to three groups: a control group,
a D-GalN group receiving a single i.p. injection of D-galactosamine (400 mg kg1 BW) and a neo-
stigmine-treated D-GalN group receiving a single i.p. injection of D-galactosamine followed 24 h
later by i.p. injection of neostigmine methylsulfate 0.25% (80 lg kg1 BW) three times daily for
3 successive days. Rats were sacriﬁced 24 h after the last injection. Plasma levels of liver transam-
inases, total proteins, albumin, prothrombin, total bilirubin and hepatic levels of superoxide dismu-
tase and malondialdehyde were measured. Liver expression of cytokines (HMGB-1, TNF-a and IL-
10) and histopathology were evaluated.
Results: Neostigmine attenuated liver dysfunction and improved liver synthetic and excretory
functions, reduced proinﬂammatory cytokine HMGB1 (95% CI 0.33–1.09) and TNF-a (95% CIthesiology and Intensive Care,
amoun St., Nasr City, Cairo
m (R.S. Bondok).
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52 R.S. Bondok et al.1.26–2.06) expression compared to D-GalN group (95% CI 2.67–4.73 and 7.33–14.53, respectively,
P< 0.001) and increased expression of the anti-inﬂammatory cytokine IL-10 in liver tissue (95%
CI 2.49–4.17 vs 0.04–0.21 in D-GalN group, P< 0.001). Neostigmine also signiﬁcantly increased
antioxidant level, and decreased oxidative burden caused by D-GaIN.
Conclusion: Neostigmine improved liver function in a rat ALF model through an anti-inﬂamma-
tory activity.
Open access under CC BY-NC-ND license.
© 2013 The Egyptian College of Critical Care Physicians. Production and hosting by Elsevier B.V.Acute liver failure (ALF) may lead to massive liver cell
death and severe liver dysfunction, multiorgan failure and
death, and thus represents a major therapeutic challenge [1].
It necessitates intensive care and the close cooperation of liver
surgeons, hepatologists, intensivists and anesthesiologists spe-
cialized in liver disease. The use of emergency liver transplan-
tation in ALF is limited by organ availability; newer
therapeutic options are required to bridge to transplantation
or to treat patients unsuitable for liver transplantation.
Hepatic and circulating inﬂammatory cytokines are central
in the pathophysiology of ALF, being involved in hepatocyte
necrosis, extrahepatic complications and hepatocyte regenera-
tion [2]. Hepatocellular apoptosis is a crucial step in acute liver
injury, functioning as a signal for leukocyte migration and at-
tack on parenchymal cells, which establishes a vicious circle of
aggravated leukocytic inﬂammation and cell death [3].
Although it is not yet fully understood whether apoptosis or
necrosis predominates in acute liver injury [4], it is clear that
treatment should target the downstream consequences of
inﬂammatory activation. It may therefore be important to
identify the signals that modulate the subsequent cellular and
molecular mechanisms responsible for liver cell death, in order
to develop treatments to encourage regeneration, rather than
cell death [4–6].
Besides the known cholinergic pathways involved in auto-
nomic regulation, the ‘cholinergic anti-inﬂammatory pathway’
that inhibits macrophage cytokine production has been discov-
ered [7–9]. Acetylcholine (ACh) can interact with a-7 subunits
of nicotinic ACh receptors (a-7 nACh R), leading to inhibition
of cytokine release [7–9]. Cholinergic activation has been
shown to have anti-inﬂammatory effects [10–14]. Hepatic stel-
late cells have been recently shown to express functional nACh
R subunits including an a-7 subtype [15].
As with sepsis, ALF is associated with overwhelming acti-
vation of the immune system. In a murine sepsis model, Hofer
et al. demonstrated the protective effects of the cholinesterase
inhibitor neostigmine, which reduces the production of proin-
ﬂammatory cytokines, TNF-a, IL-1b and IL-6, and improves
survival [11]. The present study was designed to test the
hypothesis that neostigmine, a cholinesterase inhibitor, can
modulate liver functions, pro inﬂammatory cytokines
HMGB-1, TNF-a and the anti-inﬂammatory cytokine IL-10
in an ALF model.
Materials and methods
Experimental animals
Thirty-six adult female Wistar rats weighing 200–250 g were
purchased from the experimental animal farm (Giza, Egypt)
and maintained in the Physiology Department Animal Houseunder standard conditions of boarding. They were given free
access to regular diet and water. The care of animals and all
experimental procedures were approved by the Research Eth-
ics Committee at the Faculty of Medicine, Ain-Shams Univer-
sity, Egypt (FMASU REC No. 1032/2011).
Experimental protocol
The rats were randomly allocated to three groups of twelve:
Control group (C) rats received normal saline as a single intra-
peritoneal (i.p.) injection (1.5 ml kg1, (as solvent of D-galac-
tosamine), followed 24 h later by i.p. injection of normal
saline three times daily for 3 successive days (1 ml kg1, as sol-
vent of neostigmine). Group D-GalN rats received a single i.p.
injection of D-galactosamine (Sigma, St. Louis, MO, USA) at a
dose of 400 mg kg1 body weight (BW) [16] followed 24 h later
by i.p. injection of normal saline three times daily for 3 succes-
sive days. Neostigmine-treated D-galactosamine (group N) rats
received a single i.p. injection of D-galactosamine at a dose of
400 mg kg1 BW, followed 24 h later by i.p. injection of neo-
stigmine methylsulfate 0.25% (EIPICO, Egypt) at a dose of
80 lg kg1 BW three times daily for 3 successive days [11].
All animals were sacriﬁced 24 h after the last injection i.e. at
day 5. A graphical depiction of the study design is presented
in Figure 1.
Experimental procedures
The rats, having had free access to water, were weighed on the
day of experiment after an overnight fast and then anesthetized
by i.p. injection of thiopental sodium (EIPICO, Egypt),
40 mg kg1 BW. The abdominal aorta was then exposed and
two blood samples collected: one into a tube containing
3.2% sodium citrate for determination of prothrombin time
(PT) and the other into a heparinised tube for determination
of plasma alanine transferase (ALT), aspartate transferase
(AST), alkaline phosphatase (ALP), total proteins, albumin
(ALB) and total bilirubin (TBIL).
The liver was removed from the abdominal cavity. The left
lobe was ﬂushed with physiological saline and stored at
80 C for subsequent measurement of superoxide dismutase
(SOD) activity and malondialdehyde (MDA) content. The
right lobe was divided into two portions; one was stored at
80 C for later determination of gene expression of
HMGB-1, TNF-a and IL-10 and the other was used for histo-
logical study.
Liver function assay
Plasma ALT and AST activities were estimated by Reitman-
Frankel colorimetric methods whereas TBIL analysis was car-
Figure 1 Flowchart illustrating animal enrollment, randomization, experimental protocol, and analysis of data.
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Quimica Clinica Aplicada S.A., Spain. Plasma ALP activity,
total proteins and ALB were determined by quantitative color-
imetric method using kits supplied by Biolabo SA, France and
Stanbio-laboratory, U.S.A. PT was determined according to
the method of Caen et al., using Neoplastine Cl plus kits sup-
plied by Diagnostica Stago, France [17].
Oxidant/antioxidant markers
Antioxidant enzyme SOD activity and MDA concentration, as
indices of lipid peroxidation products, were assayed in the li-
ver. Liver homogenates were prepared by homogenizing liver
tissues (200 mg ml1) in cold buffer (50 mM potassium phos-
phate, pH 7.5, and 1 mM EDTA) for SOD and liver tissues(100 mg ml1) in 1.15% KCl buffer for MDA, using tissue
homogonizer (IKA-WERK, Ultra-Turrax, West Germany).
Tissue homogenates were centrifuged at 4000 rpm for 15 min
and the supernatants stored at 80 C. SOD was measured
by its inhibition of phenazine methosulphate-mediated reduc-
tion of nitroblue tetrazolium dye [18]. MDA was determined
by spectrophotometric measurement of the color occurring
during the reaction of MDA with thiobarbituric acid [19]. Kits
were supplied by Bio-diagnostic, Egypt.
Measurement of HMGB-1, TNF-a and IL-10 gene expression in
the liver by quantitative real-time PCR (RT-qPCR)
Specimens of liver were subjected to tissue disruption and
homogenization with a rotor–stator homogenizer. Total
54 R.S. Bondok et al.RNA was extracted immediately according to the manufac-
turer’s instructions of MagNA Pure Compact Nucleic Acid
Isolation Kit I (Cat. No. 03730964001-Roche, Germany) using
the MagNa Pure Compact Instrument (Roche-Germany)
which is a fully automated system. The total yield of RNA
was determined spectrophotometrically. The extracted puriﬁed
RNA was converted into complementary DNA (cDNA) by re-
verse transcriptase and ampliﬁed by Light Cycler-RNA Ampli-
ﬁcation Kit SYBR Green I (Cat. No. 2015137).The kit is for a
one-step RT-PCR using the Light Cycler 2.0 System (Roche,
Germany). RT-qPCR was performed with speciﬁc primers cor-
responding to the proinﬂammatory cytokine genes: HMGB-1,
TNF-a, and IL-10. Glyceraldehyde-3-phosphate dehydroge-
nase (GAPDH) primer was used to normalize the amount of
RNA in each sample. The forward and reverse primers for:
HMGB-1 were: 50-TGTCCACACACCCTGCATATTG-30
and 50- AATCCCATGGTGTGACAGAATTGA-30; IL-10
were: 50-CTTGCACTACCAAAGCCACA-30 and 50-AAGTG
TGGCCAGCCTTAGAA-30; TNF-a were: 50-ATCTTCTC
AAAATTCGAGTGACAA-30 and 50-TGGGAGTAGACAA
GGTACAACCC-30; and GAPDH were: 50-TTCACCACC
ATGGAGAAGGC-30 and 50-GGCATGGACTGTGGTCAT
GA-30.
The speciﬁcity of the ampliﬁcation products was controlled
using a melting curve analysis. The thermal cycling proﬁle con-
sisted of: initial denaturation at 95 C for 10 min followed by
40 cycles of denaturation at 95 C for 30 s, annealing at
60 C for 30 s and ﬁnal elongation at 72 C for 30 s for 40 cy-
cles. The melting temperature proﬁle was assessed for each
PCR run to conﬁrm the speciﬁcity of PCR products.
The levels of HMGB-1, TNF-a and IL-10 transcripts were
normalized to the housekeeping gene GAPDH. mRNA expres-
sion was calculated using the standard curve.Histological examinations
Coded histological slides of rat livers were examined by two
independent assessors in the research group, blinded with re-
spect to group allocation.Light microscopic study (LM)
Small liver slices were ﬁxed in 10% formalin and processed to
form parafﬁn sections of 5 lm thickness and stained with
Hematoxylin and Eosin (H&E). These sections were graded
numerically to assess the histological features in acute hepatic
injury. They were semi-quantitatively evaluated in terms of
vacuolar degeneration in hepatocytes, eosinophility of hepato-
cytes and mononuclear cellular inﬁltration. Two independent
assessors with experience in histological assessment of liver in-
jury were asked to rate the appearance of 5 high power ﬁelds
per 5 different sections in each rat under study. The morpho-
logical changes were assessed independently and graded as fol-
lows: 0 = no observed changes, 1–2 = mild changes, 3–
4 = moderate changes and 5–6 = severe changes [20]. Each
assessor was asked to view and score the same set of slides
on a second occasion following recoding (re-blinding). Sec-
tions were randomly coded, by a third individual, on both
occasions. Randomization codes were broken after each
assessment session. Scores reported are the mean of the two
scores.Electron microscopic study (TEM)
Small liver specimens (1 mm3) were ﬁxed in phosphate-buf-
fered gluteraldehyde and processed to form capsules. Ultra-
thin sections (50–60 nm thickness) were cut using an ultra-
microtom. Sections were mounted on copper grids and stained
with a saturated solution of uranyl acetate followed by lead cit-
rate. Ultra-thin sections were examined and photographed by
JEM-1200EXII transmission electron microscope in Faculty of
Science, Ain-Shams University.
Statistical analysis
Data were analyzed using the Statistical Package for Social
Sciences (SPSS) version 20 (SPSS Inc., Chicago, IL). Nor-
mality of quantitative data distribution was tested using the
Shapiro Wilk test. Normally distributed numerical data were
presented as mean ± SD with 95% Conﬁdence Interval (CI)
and between-group differences were compared parametrically
using one-way analysis of variance (ANOVA). The Scheffe´
post hoc test was used for pairwise comparisons whenever
the one way ANOVA revealed a signiﬁcant difference. For in-
ter-group comparisons of numerical data exhibiting skewed
distribution, the Kruskal Wallis test was used, and the
Mann–Whitney U test was employed post hoc whenever a sta-
tistically signiﬁcant difference was detected with the Kruskal
Wallis test. To preserve the a-error at 0.05 as set initially,
the Bonferroni method was used to correct for multiple pair-
wise comparisons with the Mann–Whitney U-test.
All reported P values are two-tailed. A corrected P value of
<0.017 for pairwise comparisons conducted with the U-test
was considered statistically signiﬁcant. Otherwise, P< 0.05
was regarded as statistically signiﬁcant.
Results
Liver function assay
Table 1 shows that D-GaIN increased plasma ALT, AST,
ALP, TBIL and prolonged PT compared to controls. In rats
treated with neostigmine 24 h after D-GaIN injection, there
was lower ALT, AST, ALP, TBIL and PT levels compared
to D-GaIN group (P< 0.001).
Oxidant and antioxidant markers
D-GaIN increased MDA as compared to control
(1.88 ± 0.61 Ug1; 95% CI 1.49–2.26 Ug1; vs 0.79 ±
0.36 Ug1, P< 0.001). Neostigmine protected against peroxi-
dative damage caused by D-GaIN, reducing hepatic MDA
(0.81 ± 0.43 Ug1; 95% CI 0.54–1.08 Ug1; P< 0.001). Con-
versely, D-GaIN reduced SOD levels (346.11 ± 166.24 lmol
g1) (95% CI 240.49–451.73 lmol g1) as compared to control
(1685.27 ± 674.84 lmol g1) (P< 0.001). Whereas, neostig-
mine increased liver SOD (798.14 ± 458.66 lmol g1; 95%
CI 506.72–1089.56 lmol g1; P< 0.001) as compared to group
D-GalN (Table 1).
Liver HMGB-1, TNF-a and IL-10 expression
D-GalN-induced ALF led to an increase in proinﬂammatory
cytokines. HMGB-1expression increased (95% CI 2.67–4.73;
Table 1 Liver function assays, body weight and oxidant and antioxidant markers.
Group Control D-galactosamine Neostigmine-treated D-galactosamine
Body weight (g) 217.8 ± 39.9 225.7 ± 25.9 220.8 ± 26.5
PT (sec) 19.4 ± 2.35 88.7 ± 32.3a 27.0 ± 13.9b
ALT (U ml1) 10.6 ± 1.02 92.2 ± 10.21a 11.3 ± 1.06b
AST (U ml1) 14.9 ± 7.41 84.5 ± 11.29a 21.6 ± 9.44b
ALP (IU L1) 66.5 ± 12.74 117.4 ± 49.14a 83.9 ± 23.40b
Total proteins(g dL1) 7.43 ± 0.29 5.59 ± 0.65a 6.65 ± 0.53b
ALB (g dL1) 4.45 ± 0.62 3.03 ± 0.62a 4.37 ± 0.48b
TBIL (mg dL1) 0.397 ± 0.23 1.546 ± 0.62a 0.637 ± 0.38b
MDA (U g1) 0.79 ± 0.36 1.88 ± 0.61 a 0.81 ± 0.43 b
SOD (lmol g1) 1685.27 ± 674.84 346.11 ± 166.24a 798.14 ± 458.66b
Values presented are mean + SD.
a Signiﬁcant difference to control group P< 0.001.
b Signiﬁcant difference to D-galactosamine group P< 0.001. ALT= alanine transferase, AST = aspartate transferase, ALP = alkaline
phosphatase, ALB= albumin, TBIL = total bilirubin, MDA=malondialdehyde, and SOD= superoxide dismutase.
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7.33–14.53; P< 0.001 compared to control) (Figure 2). Treat-
ment with neostigmine reduced these increases (95% CI 0.33–
1.09; P< 0.001 and 95% CI 1.26–2.06; P< 0.001, HMGB-1
and TNF-a respectively) (Figure 2). Expression of the anti-
inﬂammatory cytokine IL-10 was unchanged in D-GalN
(95% CI 0.04–0.21; P= 0.853) (Figure 2), but neostigmine
treatment markedly increased its expression in liver tissue
(95% CI 2.49–4.17; P< 0.001) (Figure 2).
Liver Histopathology
Examination of H & E stained sections of D-GalN group
showed focal and bridging hepatic necrosis accompanied by di-
lated blood sinusoids and congested portal venules and central
veins. Vacuolated and degenerated hepatocytes appeared
mainly in zones I and II of the hepatic lobule, with increased
eosinophility of hepatocytes with pyknotic or karyolitic nucleiFigure 2 Hepatic gene expression of high mobility group box-1
(HMGB-1), tumor necrosis-a (TNF-a) and interleukin (IL)-10.
Error bars represent 95% Conﬁdence Interval. (a) Signiﬁcantly
different from control group P< 0.001. (b) Signiﬁcantly different
from D-galactosamine group P< 0.001.(P< 0.001) (Table 2). Further, mononuclear cellular inﬁltra-
tion was observed around portal areas, blood sinusoids and
the central vein (P< 0.001), compared to controls ( Figure
3). TEM examination of liver sections in group D-GalN
showed many lipid vacuoles in the hepatocytes, some of which
encroached on the nuclei, causing nuclear membrane irregular-
ities. The cytoplasm showed dilatation of the rough and
smooth endoplasmic reticulum (rER, and sER), dilatation of
the Golgi apparatus and disﬁgured swollen mitochondria with
poorly distinguishable cristae. In addition, apparently wide
spaces of Disse were noticed containing collagen ﬁbers with
loss of normal hepatocytic microvilli (Figure 4).
Treatment with neostigmine clearly improved D-GalN-in-
duced liver damage. Figure 3 and Table 2 show the reduction
in vacuolar degeneration and necrosis, eosinophility of hepato-
cytes and mononuclear cellular inﬁltration (P< 0.001 com-
pared to group D-GalN).
Neostigmine treatment improved hepatocyte architecture,
showing fewer lipid vacuoles, reduced electron-density of mito-
chondria and less dilation of rER, sER and Golgi apparatus in
TEM examination compared to group D-GalN ( Figure 4).
Also, nuclear conﬁguration and intercellular spaces with inter-
digitating microvilli of the hepatocytes appeared comparable
to the control group (Figure 4).
Discussion
This study examined the effect of the cholinesterase inhibitor
neostigmine on D-GalN-induced ALF in rats. ALF was veri-
ﬁed chemically by raised levels of liver enzymes, prolonged
PT, increased plasma TBIL, decreased plasma levels of total
proteins and ALB. Histological and ultrastructural examina-
tion of the liver also conﬁrmed D-GalN-hepatotoxicity. Neo-
stigmine attenuated liver dysfunction and improved liver
synthetic and excretory functions, reduced proinﬂammatory
cytokine TNF-a and HMGB1 expression and increased
expression of the anti-inﬂammatory cytokine IL-10 in liver
tissue.
As treatment of human acute liver failure cannot usually be
initiated at the time of onset, even successful experimental
treatments initiated immediately after or prior the onset of
ALF provide little rationale for clinical development
[16,21,22]. Liver-borne inﬂammation occurs at about 6–12 h
Figure 3 Photomicrographs of rat liver sections: (A) control group, showing normal hepatic lobule. D-galactosamine group showing: (B)
vacuolated hepatocytes (V) dilated blood sinusoids in zone I (D) and mononuclear cellular inﬁltration in the portal area (›); (C)
eosinophilic degeneration of hepatocytes (›) and (D) conﬂuent necrosis of hepatocytic plates (N), congested portal vein (›) and congested
blood sinusoids (D). (E) Neostigmine-treated group showing improvement of liver architecture. (H&E: A, B, D, E 200· – C 400·).
Table 2 Histopathological scores in rat liver sections.
Group Control D-galactosamine Neostigmine treated D-galactosamine
Degeneration and necrosis 0 (0–0) 4.5 (4–5)a 1.5 (1–2)a,b
Increase eosinophility 0 (0–0.75) 5 (4–5)a 1(1–2)a,b
Inﬂammatory cell inﬁltration 0 (0–1) 3 (3–4)a 1.5 (1–2)a,b
Data are presented as median (interquartile range).
a Signiﬁcant difference to control group P< 0.001.
b Signiﬁcant difference to D-galactosamine group P< 0.001.
56 R.S. Bondok et al.after the administration of D-GalN [6,16,23]. High mobility
group box 1 (HMGB1) protein has been identiﬁed as a late
mediator of endotoxin lethality, HMGB1 protein itself can
cause an acute inﬂammatory response manifested by increased
production of proinﬂammatory cytokines and neutrophil accu-
mulation. The delayed kinetics of HMGB1 protein release
indicate that this protein is a distal mediator of acute inﬂam-
mation, it can be detected 24 h after monocyte activation
[24]. In our model, to study the effect of neostigmine in a clin-
ically relevant time frame, we started drug therapy 24 h after
D-GalN intake.
TNF-a and late pro-inﬂammatory cytokine HMGB-1 are
critical acute liver failure mediators, and interventions that
suppress their activity can improve survival [6,16,22,23,25].
HMGB-1 is released several hours later than other proinﬂam-
matory cytokines [24]. A reciprocal functional relationship was
found between the activities of the early TNF-a and late
HMGB-1 cytokines. HMGB-1 is a potent activator of mono-
cyte cytokine release, and its release is promoted by TNF-a
[26]. The anti-inﬂammatory activity of neostigmine in an
ALF model is shown by its inhibition of TNF-a and
HMGB-1 expression and enhanced release of the anti-inﬂam-
matory cytokine IL-10.
The rate of albumin synthesis may be signiﬁcantly altered in
the critically ill. In the acute-phase response to trauma,inﬂammation or sepsis, there is a decrease in the rate of tran-
scription of albumin mRNA and the synthesis of albumin [27].
Proinﬂammatory cytokines, IL-6 and TNF-a both act to re-
duce gene transcription and thereby the synthesis of albumin
[28]. Induced inﬂammation in rats decreased the concentration
of albumin mRNA and the rate of albumin synthesis [29]. As
well, a sustained inﬂammatory response in critical illness may
lead to prolonged inhibition of albumin synthesis [27]. Neo-
stigmine improved total protein and albumin levels in D
GalN-induced ALF rats, this could be implicated by its anti-
inﬂammatory activity through the reduction of the proinﬂam-
matory cytokines TNF-a and HMGB-1.
Neostigmine inhibits acetylcholine inactivation and thus
prolongs the excitation of cholinergic synapses, potentially
enhancing cholinergic activity. The ‘‘cholinergic anti-inﬂam-
matory pathway’’ has been described as a mechanism for neu-
ronal control of inﬂammation via the efferent vagus nerve
[7,9]. Wang et al. showed that a-7nACh R is the molecular link
between the brain and the immune system in the cholinergic
anti-inﬂammatory pathway [8]. The activation of immune cell
a-7 nACh R regulates the intracellular signals that control
cytokine transcription and translation [8,25].
Cholinergic anti-inﬂammatory pathway activation has been
reported in animal models of systemic inﬂammatory reactions
and cardiac dysfunction [11,12]. The expression of functional
Figure 4 Electron micrographs of rat liver sections of: (A) Control group. D-galactosamine group: (B) irregular nuclear membrane and
multiple lipid vacuoles (L); (C) dilated rER (›), dilated sER (D), dilated Golgi apparatus (m) and disﬁgured swollen mitochondria (M).
(D) Neostigmine-treated group showing improvement of hepatocyte structure. (TEM: A, B, D 10,000·, scale bar = 2 l – C 7500·, scale
bar = 500 nm).
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cytes, including the a-7 subtype, was recently discovered by
Soeda et al. [15].
We chose a dose of 80 lg Kg1, three times daily, which
Hofer et al. have shown to have remarkable anti-inﬂammatory
effects in a murine sepsis model [11]. Freeling et al. showed
similar effects [12], whereas Kox et al. showed no beneﬁt of
neostigmine in a ventilator-induced lung inﬂammation model
[30]. This could be attributed to the relatively mild inﬂamma-
tory response in their model (compared to fulminant sepsis or
ALF), which probably was not severe enough to activate the
cholinergic anti-inﬂammatory pathway [30] – this pathway is
regarded as a reﬂex response to control excessive inﬂammation
[9]. Other possible explanations might be their use of atropine
as a part of the anesthetic regime, which by blocking the nico-
tinic ACh receptor response reduces the mitigating effects of
acetylcholine on TNF-a expression [31,32], or compartmental-
ization. Kox et al. evaluated effects on mechanical ventilation-
induced lung inﬂammation [30], the present study assessed li-
ver inﬂammation while Hofer et al. investigated sepsis-induced
systemic inﬂammation [11].
The different timings and organs may explain the results;
the capacity of cells from different organs to produce inﬂam-
matory cytokines can be either enhanced, unchanged, or de-
creased depending upon the experimental models [33]. Akinci
et al. also failed to detect any protective effects of neostigmineat doses of 100 lg Kg1 in a mouse model of endotoxin-in-
duced septic-shock. Interestingly, at higher dosages
(300 lg Kg1), a decrease in interstitial inﬂammation was ob-
served but mortality was increased, possibly because of non-
speciﬁc parasympathetic effects such as those on the
cardiovascular system [34].
Inhibition of cytokine biosynthesis by the cholinergic anti-
inﬂammatory pathway is caused by cholinergic neurotransmis-
sion acting on a-7nACh R [7–9]. Both direct electrical stimula-
tion of the vagus nerve [10,35] and application of a-7nACh R
agonists [11,13,14,30] inhibit the synthesis of TNF-a
and HMGB-1. Neostigmine also exerts profound cholinomi-
metic effects via inhibition of peripheral anticholinesterase.
Although in our ALF model, neostigmine was anti-inﬂamma-
tory, the actual mode of action is unclear.
The increased hepatic MDA, the end product of lipid per-
oxidation, and decreased hepatic SOD, an antioxidant, are
convenient markers of oxidative stress. Reactive oxygen spe-
cies (ROS) play a critical role in the induction and propagation
of liver disease [16]. Massive ROS production in response to
ischemia or toxic injury to the liver causes lipid peroxidation
of cellular membranes, and protein and DNA oxidation
[16,36]. The main sources of ROS are hepatocyte mitochon-
dria, activated macrophages (Kupffer cells) and inﬁltrating
neutrophils [16,37]. ROS can trigger the translocation of nucle-
ar factor-kB (NF-jB) to the nucleus and activate inﬂammatory
58 R.S. Bondok et al.cytokines that in turn contribute to further production of ROS
[16,37]. Hepatocytes can release HMGB-1 in response to oxi-
dative stress [26]. HMGB-1 also stimulates neutrophil ROS
production [38], and increases the activation of NF-jB result-
ing in an increased cytokine release [39,40]. Mitochondria are
both a target and a source of ROS, which play an important
role in physiologic signaling mechanisms and in the regulation
of the apoptotic pathway. The latter triggers intracellular free
radical production during the induction of cell death [16,41].
Our electron microscopy ﬁndings included disﬁgured mito-
chondrial structure, dilatation of sER and rER, and nuclear
membrane irregularities, suggesting increased free radical
activity in D-GalN-induced ALF. Treatment with neostigmine
reduced hepatic MDA and increased hepatic SOD, reﬂecting
an upregulation of antioxidant defense mechanisms. Further,
focal and bridging necrosis, increased eosinophility of hepato-
cytes and inﬂammatory cell inﬁltration induced by D-GalN
were signiﬁcantly less with neostigmine. The toxic fatty inﬁltra-
tion we observed in the liver parenchyma is especially signiﬁ-
cant. Oxidative stress originating from increased intracellular
levels of fatty acids is implicated in hepatocellular injury in ste-
atosis [16,42].
We found that D-GalN-induced hepatocyte lipid accumula-
tion was markedly reduced by neostigmine, which we assume
to ameliorate hepatic steatosis through an anti-inﬂammatory
activity which is likely to reduce oxidative stress-induced
inﬂammation. The beneﬁcial effect of neostigmine on this
ALF model is also emphasized by the improvement of hepatic
architecture and restoration of hepatic integrity. Cholinergic
activation by means of cholinesterase inhibition is already
being used clinically, as in the treatment of the central anticho-
linergic syndrome or as an adjuvant in pain therapy [43].
To our knowledge this is the ﬁrst study that has explored
this topic. In this study we pharmacologically activated the
cholinergic anti-inﬂammatory pathway in a way that could
also be used in patients.
Limitations of the study
Whether neostigmine effects are partially or totally mediated
via the a-7nACh receptor, this is considered a limitation of
the study and would require further experimental studies using
a selective a-7nAChR agonist. Another limitation was the dif-
ﬁculty in obtaining the initial baseline laboratory data from
the rats.
Clinical implications
Cholinesterase inhibition via neostigmine might be considered
as a therapeutic concept in patients suffering acute hepatic fail-
ure which may provide a rationale for further conﬁrmation
and exploration and may have important implications in the
development of new treatment strategies to bridge selected pa-
tients to transplantation or to treat those not considered can-
didates for liver transplantation.
Conclusion
We have demonstrated that cholinesterase inhibition with neo-
stigmine counteracts D-GalN-induced ALF through an anti-
inﬂammatory activity.References
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